Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

The average age for someone diagnosed with Kidney Cancer in the U.S. is 65. But one local man’s decades-long battle with ...

These findings should inform public health policies aimed at guaranteeing access to effective combination therapies. Renal cell carcinoma (RCC) is one of the most common malignancies of the ...

Treatment Pattern and Outcome of Locally Advanced Rectal Cancer in Resource-Constrained Countries: Experience at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia A retrospective study was ...

Recent therapeutic advances have changed the treatment landscape of metastatic renal cell carcinoma. Unfortunately, the seven agents now available are not based on biomarkers that would indicate ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma. The United States Food ... nephritis with renal dysfunction and skin ...

Patients with intermediate- or high-complexity renal tumors generally have similar outcomes with RAPN and OPN, data suggest.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC); or as a single agent, for the treatment of adults with metastatic ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...